Arend, Rebecca C.; Scalise, Carly B.; Gordon, Emily R.; Davis, Allison M.; Foxall, McKenzie E.; Johnston, Bobbi E.; Crossman, David K.; Cooper, Sara J. published the artcile< Metabolic alterations and WNT signaling impact immune response in HGSOC>, Electric Literature of 112-63-0, the main research area is high grade serous ovarian cancer immune response signalling alteration.
Purpose: Our study used transcriptomic and metabolomic strategies to determine the mol. profiles of HGSOC patient samples derived from primary tumor and ascites cells. These data identified clin. relevant heterogeneity among and within patients and highlighted global and patient-specific cellular responses to neoadjuvant chemotherapy (NACT). Exptl. Design: Tissue from 61 treatment-naïve patients with HGSOC were collected. In addition, 11 benign, 32 ascites, and 18 post-NACT samples (matched to the individual patient′s pre-NACT sample) were collected. RNA sequencing (RNA-seq) was performed on all samples collected. Two-dimensional spatial proteomic data was collected for two pairs of pre- and post-NACT. Untargeted metabolomics data using GCxGC-MS was generated for 30 treatment-naive tissues. Consensus clustering, anal. of differential expression, pathway enrichment, and survival analyses were performed. Treatment-naïve HGSOC tissues had distinct transcriptomic and metabolomic profiles. The mesenchymal subtype harbored a metabolomic profile distinct from the other subtypes. Compared with primary tumor tissue, ascites showed significant changes in immune response and signaling pathways. NACT caused significant alterations in gene expression and WNT activity, and this corresponded to altered immune response. Overall, WNT signaling levels were inversely correlated with immune cell infiltration in HGSOC tissues and WNT signaling post-NACT was inversely correlated with progression-free survival. Our study concluded that HGSOC is a heterogenous disease at baseline and growing mol. differences can be observed between primary tumor and ascites cells or within tumors in response to treatment. Our data reveal potential exploratory biomarkers relevant for treatment selection and predicting patient outcomes that warrant further research.
Clinical Cancer Research published new progress about Adaptive immunity. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Electric Literature of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics